Vaxcyte(PCVX) - 2024 Q4 - Earnings Call Presentation

Corporate Presentation February 25, 2025 Highlights: Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise Positive Phase 1/2 Adult Data for VAX-31 and VAX-24 Validate Potential of Site-Specific, Carrier-Sparing Platform POTENTIAL BEST-IN-CLASS PCV FRANCHISE HIGHLY ATTRACTIVE PCV MARKET Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, ...